GNS 561

Drug Profile

GNS 561

Alternative Names: GNS-561

Latest Information Update: 23 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genoscience
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Autophagy inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatocellular carcinoma

Most Recent Events

  • 04 Apr 2018 Phase-I/II clinical trials in Hepatocellular carcinoma (Late-stage disease, Metastatic disease) in Belgium (unspecified route) (NCT03316222)
  • 24 Oct 2017 Genoscience plans a phase I/II trial for Hepatocellular carcinoma (Late-stage disease, Metastatic disease) in January 2018 (NCT03316222)
  • 05 Apr 2017 Pharmacodynamic and adverse events data from a preclinical trial in Hepatocellular carcinoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top